577 Circulating tumor DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients
Explore this paper's citation graph
- Type
- article
- Published
- 2017-10-01
- Cited by
- 0
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W2752773766
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:90976800
Keywords
Nivolumab, Medicine, Melanoma, Circulating tumor DNA, Metastatic melanoma
References
No references recorded for this paper.
Cited by
No citing papers recorded for this paper.
Related papers
- Nivolumab success in untreated metastatic melanoma.
- LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
- Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
- C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma
- P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab: Topic: IT
- Clinical characteristics and outcomes associated with molecular status and treatment with vemurafenib in metastatic melanoma (MM) in a real-world setting: Comparison of four groups.
- Cogan-Like Syndrome Following Nivolumab Immunotherapy for Metastatic Cutaneous Melanoma
- Radiological identification of rapid progressions in advanced NSCLC patients treated with nivolumab.